Multitude, Inc.

Antengene Discovery Limited

Bing Hou

Xun Meng

Shu-Hui Liu

Guangcun Cheng

Na Wang

Shaofei Zhang

Ming Zhang

Wei Wang

Guoqiang Dai

Bin Jiang

Jay Mei

Junli Liu

Ya Kong

Yulong He

Lulu Jiang

Antibodies specific to folate receptor alpha (a.k.a. folate receptor 1 or FOLR1) and uses thereof for therapeutic and diagnostic purposes. Also provided herein are chimeric antigen receptors (CARs) comprising an extracellular antigen-binding fragment that binds FOLR1 and immune cells expressing such.

Antibodies specific to folate receptor alpha

Antibodies specific to MUC18 (a.k.a. MCAM or CD146) and uses thereof for therapeutic and diagnostic purposes are provided. Also provided herein are chimeric antigen receptors (CARs) comprising an extracellular antigen-binding fragment that binds MUC18 and immune cells expressing such.

Antibodies specific to MUC18

Antibodies specific to MUC18 (a.k.a. MCAM or CD146) and antibody-drug conjugates (ADCs) comprising such. Also provided herein are uses the the anti-MUC18 antibodies or ADCs for therapeutic and diagnostic purposes.

Antibodies having binding specificity to CD44 v7/8, (a.k.a. CD44 variant 7/8) and antibody-drug conjugates (ADCs) or chimeric antigen receptors comprising such. Also provided herein are uses the anti-CD44 v7/8 antibodies, the ADCs, or immune cells expressing the chimeric antigen receptors for therapeutic and diagnostic purposes.

Antibodies specific to CD44

The present application provides novel PRMT5 and/or MTA-cooperative PRMT5 inhibiting compounds, or pharmaceutically acceptable salts thereof. The present application also provides pharmaceutical compositions comprising one or more of the compounds, or pharmaceutically acceptable salts thereof as an active ingredient, and the use of the compounds, or pharmaceutically acceptable salts thereof in the treatment of diseases or disorders, including cancers.

PRMT5 inhibiting compounds and uses thereof

Growing community of inventors

Shanghai, China

Bing Hou